Elanco closes $444M purchase of biopharma co.August 31, 2021Elanco Animal Health has expanded its reach into the veterinary dermatology market with the $444-million acquisition of biopharma company, Kindred Biosciences.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Elanco acquires biopharma co. in $440M dealJune 16, 2021A major player in the global animal health industry has expanded its reach into the veterinary dermatology market with the purchase of a biopharmaceutical company.
Parvo preventative picks up speedDecember 29, 2020Elanco Animal Health is set to acquire the global rights to Kindred Biosciences’ proprietary KIND-030, a monoclonal antibody being developed for the treatment and prevention of canine parvovirus.
Preventative for deadly puppy disease may be imminentSeptember 18, 2020An efficacy study of a monoclonal antibody targeting canine parvovirus has shown complete efficacy in its prevention, its maker says.
Biopharma company partners to make oral COVID-19 vaccineMay 20, 2020A vaccination tablet for the novel coronavirus might soon be available, thanks to a new partnership between KindredBiosciences and Vaxart.
Canine parvovirus treatment may be in the worksAugust 19, 2019Veterinarians may soon have access to an antibody effective in the treatment of canine parvovirus (CPV).
KindredBio named AAHA Advantage's new vendorApril 25, 2019Kindred Biosciences has been named American Animal Hospital Association (AAHA) Advantage's newest vendor. As part of the deal, the biopharmaceutical company will provide marketing and education funds to enhance AAHA's existing educational programs and resources. "At KindredBio, we support veterinary science at every level, whether it's in the laboratory where we develop innovative technologies or in the exam room where veterinarians put science into action," says KindredBio president and chief operating officer, Denise Bevers. "As such, we are proud to join forces with the AAHA."
